CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Standard (specific) therapy for COVID-19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug182 Anti-COVID-19 human immunoglobulin Wiki 1.00
drug2442 Taking blood samples for analyzing progesterone levels Wiki 1.00
drug472 COVID-19 convalescent plasma Wiki 0.50

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.

A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.

NCT04395170 Coronavirus Disease 2019 (COVID-19) Biological: COVID-19 convalescent plasma Biological: Anti-COVID-19 human immunoglobulin Drug: Standard (specific) therapy for COVID-19
MeSH:Coronavirus Infections

Primary Outcomes

Description: Admission to the intensive care unit with the requirement of mechanical ventilation (invasive or non-invasive) due to Acute Respiratory Distress Syndrome by COVID-19.

Measure: Admission to ICU and/or mechanical ventilation

Time: One year

Secondary Outcomes

Description: Time in the hospital from admission to discharge or death.

Measure: Length of hospital stay

Time: One year

Description: Neutralizing antibody (IgG) titers against COVID-19

Measure: Neutralizing antibody (IgG) titers against COVID-19

Time: One year

Description: Non-serious adverse events (NSAEs) and serious adverse events (SAEs)

Measure: Safety - Adverse events

Time: One year

Description: Overall mortality

Measure: Death

Time: One year


No related HPO nodes (Using clinical trials)